Literature DB >> 21839030

Treatment of von Willebrand disease with FVIII/VWF concentrates.

Giancarlo Castaman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839030      PMCID： PMC3159911          DOI： 10.2450/2011.003S

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  13 in total

1.  Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease--single center comparison of four different assays.

Authors:  A B Federici; M T Canciani; I Forza; G Cozzi
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Old concepts and new developments in the study of platelet aggregation.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

3.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).

Authors:  A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 4.  Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

Authors:  Giancarlo Castaman; Augusto B Federici; Francesco Rodeghiero; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

Review 5.  Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.

Authors:  Ulrich Budde; Hubert J Metzner; Heinz-Georg Müller
Journal:  Semin Thromb Hemost       Date:  2006-09       Impact factor: 4.180

Review 6.  Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease.

Authors:  F Rodeghiero; G Castaman; D Meyer; P M Mannucci
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

7.  Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.

Authors:  G Castaman; F Rodeghiero; A Tosetto; A Cappelletti; F Baudo; J C J Eikenboom; A B Federici; S Lethagen; S Linari; J Lusher; M Nishino; P Petrini; A Srivastava; J S Ungerstedt
Journal:  J Thromb Haemost       Date:  2006-10       Impact factor: 5.824

8.  Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.

Authors:  Giancarlo Castaman; Alberto Tosetto; Augusto B Federici; Francesco Rodeghiero
Journal:  Thromb Haemost       Date:  2011-01-25       Impact factor: 5.249

9.  The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor.

Authors:  Jeroen C J Eikenboom; Giancarlo Castaman; Pieter W Kamphuisen; Frits R Rosendaal; Rogier M Bertina
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

10.  A comparative in vitro evaluation of six von Willebrand factor concentrates.

Authors:  S Lethagen; M Carlson; A Hillarp
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287
View more
  4 in total

1.  A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Authors:  Flora Peyvandi; Giancarlo Castaman; Paolo Gresele; Raimondo De Cristofaro; Piercarla Schinco; Antonella Bertomoro; Massino Morfini; Gabriella Gamba; Giovanni Barillari; Víctor Jiménez-Yuste; Cristoph Königs; Alfonso Iorio; Augusto B Federici
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

Review 2.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 3.  Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Authors:  Jessica M Heijdra; Marjon H Cnossen; Frank W G Leebeek
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

4.  One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients.

Authors:  Nico C B de Jager; Laura H Bukkems; Jessica M Heijdra; Carolien H C A M Hazendonk; Karin Fijnvandraat; Karina Meijer; Jeroen Eikenboom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Marjon H Cnossen; Ron A A Mathôt
Journal:  J Thromb Haemost       Date:  2019-10-21       Impact factor: 5.824
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.